AHFS Drug Information®

An Evidence-based Foundation for Safe and Effective Drug Therapy

AHFS Drug Information®
2021st Ed.
2021 © American Society of Health-System Pharmacists®
American Society of Health-System Pharmacists
ISBN-10: 1-58528-654-0 / ISBN-13: 978-1-58528-654-6
ISSN: 8756-6028
Pharmacy/Pharmacology, Drug Information, Neurology, Ophthalmology, Point of Care, Public Health

Description

With this edition, AHFS Drug Information® (AHFS® DI™) marks 63 years of continuous publication as the premier evidence-based drug compendium. The mission of AHFS® DI™ is to provide an evidence-based foundation for safe and effective drug therapy. Widely trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers, AHFS® DI™ has remained true to its mission since the first edition was published in 1959. This notable achievement of more than six decades of evidence-based medical publishing has gained AHFS® DI™ the unique distinction of being the longest published federally designated drug compendium issued by a scientific and professional society.

2021 Updates Include:

  • Drug information for COVID-19-related treatments, including use of antiviral agents such as remdesivir and lopinavir/ritonavir, SARS-CoV-2-specific monoclonal antibodies (e.g., bamlanivimab), as well as use of supporting agents such as corticosteroids, immune globulin, nitric oxide, and tocilizumab.
  • Updated information on drugs commonly used for ICU sedation in critically ill patients with COVID-19, including propofol, dexmedetomidine, and midazolam and alternative drugs such as ketamine considered in potential drug shortage situations.
  • Latest oncology therapies for the treatment of cancers associated with activating gene mutations and oncogenic gene fusions.
  • Breakthroughs in oncology approved under the FDA's accelerated approval program.
  • New information on non-oncology off-label uses.

Special Feature: A discussion of recent evidence questioning aspirin’s role in primary prevention of cardiovascular events in most adults, including the American College of Cardiology and American Heart Association’s positions.

This title updates: Monthly

Quotes, Reviews or Testimonials

"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."

-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition

"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."

-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition

“AHFS Drug Information is by far the most comprehensive and informative drug reference that I use. It offers much more in-depth information and post-marketing [after FDA approval] analysis on drugs.”

-- Jay S. Cohen, M.D., Associate Professor of Family and Preventive Medicine, University of California at San Diego Medical School - previous edition

“There is more in-depth information in AHFS DI, particularly pharmacology and kinetics. At times I especially need the unlabeled uses in AHFS Drug Information to answer questions. Other references don't include as many off-label uses.”

-- Paul Matuschka, Pharm.D., VA Medical Center, Louisville, KY - previous edition

Audience

This reference is intended to shape treatment decisions made by practitioners and clinicians and to influence public and private healthcare policies and decisions. It can be used as a valuable and unbiased pharmaceutical reference by clinical students and practitioners.

Table of Contents


Similar Resources